

Amendments to the Claims

1. *(currently amended)* A transgenic mouse whose somatic and germ cells comprise a disruption in an endogenous histamine H3 receptor gene, wherein said disruption is generated by targeted replacement with a non-functional histamine H3 receptor gene, and wherein said disruption results in said mouse having an insensitivity to amnesic effects of scopolamine as demonstrable in a passive avoidance test as compared to wild-type histamine H3 receptor mice.
2. *(original)* The mouse of claim 1, wherein said mouse is fertile and transmits the non-functional histamine H3 receptor gene to its offspring.
3. *(original)* The mouse of claim 1, wherein the non-functional histamine H3 receptor gene has been introduced into an ancestor of the mouse at an embryonic stage by microinjection of embryonic stem cells into mouse blastocysts.
4. *(original)* The mouse of claim 1, wherein the non-functional histamine H3 receptor gene has been introduced at an embryonic stage by microinjection of embryonic stem cells into a mouse blastocyst.
5. *(currently amended)* A method for producing a transgenic mouse whose somatic and germ cells comprise a disruption in an endogenous histamine H3 receptor gene, wherein said disruption is generated by targeted replacement with a non-functional histamine H3 receptor gene, said method comprising:
 - a) introducing a histamine H3 receptor gene targeting construct comprising a selectable marker into a mouse embryonic stem cell;
 - b) introducing the embryonic stem cell into a mouse blastocysts;

- c) transplanting the ~~blastocyst~~ blastocysts into a recipient pseudopregnant mouse;
 - d) allowing the ~~blastocyst~~ blastocysts to develop to term;
 - e) identifying a transgenic mouse whose genome comprises a disruption of the endogenous histamine H3 receptor gene in at least one allele; and
 - f) breeding the mouse of step (e) to obtain a transgenic mouse whose genome comprises a homozygous disruption of the endogenous histamine H3 receptor gene, wherein said disruption results in said mouse having an insensitivity to amnesic effects of scopolamine as demonstrable in a passive avoidance test as compared to wild-type histamine H3 receptor mice.
6. (original) The method of claim 5 wherein the introducing of step (a) is by electroporation or microinjection.
7. (currently amended) A cell isolated from the transgenic ~~animal~~ mouse of claim 1.